Lead Optimisation of Selective Non-Zinc Binding Inhibitors of Mmp13. Part 2.
De Savi, C., Morley, A.D., Nash, I., Karoutchi, G., Page, K., Ting, A., Gerhardt, S.(2012) Bioorg Med Chem Lett 22: 271
- PubMed: 22153941 
- DOI: https://doi.org/10.1016/j.bmcl.2011.11.034
- Primary Citation of Related Structures:  
4A7B - PubMed Abstract: 
Directed screening has identified a novel series of non-zinc binding MMP13 inhibitors that possess good levels of activity whilst demonstrating excellent selectivity over related MMPs. A lead optimisation campaign has delivered compounds with enhanced MMP13 potency, good selectivity and acceptable bioavailability profiles leading to a predicted twice-a-day dosing regimen in man.
Organizational Affiliation: 
Respiratory and Inflammation Research Area, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, UK. chris.desavi2@astrazeneca.com